Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - The premium of Haiprui's A-shares over H-shares reached 116.58%, ranking 19th among AH shares [1] - Haiprui's A-shares closed at 13.28 yuan with a 0.3% increase, and H-shares closed at 6.68 HKD with a 0.91% increase [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company operates across the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic and driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceuticals, and innovative drugs, benefiting from the depreciation of the RMB and its strong overseas revenue [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and is dedicated to providing high-quality and effective medications globally [2]. - The company’s main business segments include heparin products (20.25%), CDMO services (19.58%), and formulations (56.55%) [7]. Financial Performance - For the period from January to March 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - As of March 31, 2025, the company had a total market capitalization of 19.486 billion yuan [1]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the last three years [8]. Market Dynamics - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sectors, focusing on vaccines, innovative drugs, and raw materials [7]. Technical Analysis - The average trading cost of Haiprime's shares is 11.40 yuan, with the current stock price near a support level of 12.91 yuan [6].

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **China Healthcare** industry, particularly the **Active Pharmaceutical Ingredients (APIs)** sector and its implications for U.S. supply chains [1][11]. Core Insights and Arguments 1. **U.S. Dependence on Chinese APIs**: The U.S. has become increasingly reliant on China for essential medicines, particularly during the COVID-19 pandemic, which highlighted vulnerabilities in the supply chain [3][14]. 2. **Strategic Stockpiling Initiatives**: The Biden administration aims to produce 25% of all APIs for small molecules domestically, following a series of studies on supply chain vulnerabilities initiated during the Trump administration [3][14]. 3. **Legislative Support**: The PREPARE Act emphasizes the importance of stockpiling critical drugs and prioritizing local manufacturers, indicating a shift towards domestic production [3][14]. 4. **Investment Implications for Chinese Manufacturers**: Chinese contract manufacturers with onshore facilities in the U.S. are expected to be more resilient compared to their peers, given the increasing regulatory scrutiny on foreign facilities [3][14]. 5. **Export Growth**: Chinese pharmaceutical exports increased by 3% year-over-year in the first half of 2025, indicating a positive trend in the industry [4]. Additional Important Points 1. **FDA Drug Master Files**: Over 80% of Drug Master Files granted by the U.S. FDA are associated with facilities in India and China, underscoring the dominance of these countries in the API market [14]. 2. **Regulatory Changes**: The U.S. government has raised inspection hurdles for foreign facilities, which may further benefit Chinese manufacturers with U.S. operations [3][14]. 3. **Market Dynamics**: The call highlights the ongoing geopolitical tensions, tariffs, and FDA inspections that could impact the operational landscape for Chinese pharmaceutical companies [3][14]. Conclusion - The conference call presents a comprehensive view of the current state and future outlook of the China Healthcare industry, particularly in the context of U.S. supply chain strategies and regulatory changes. The insights provided suggest a favorable environment for Chinese manufacturers with U.S. facilities amidst increasing domestic production initiatives in the U.S. [3][14].

格隆汇8月15日丨海普瑞(09989.HK)公布，公司谨定于2025年8月29日(星期五)举行董事会会议，以(其中 包括)考虑及批准集团截至2025年6月30日止六个月的中期业绩及其刊发，派发中期股息(如有)，以及处 理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） 李鋰 董事長 （股份代號：9989） 董事會會議召開日期 深圳市海普瑞藥業集團股份有限公司（「本公司」，連同其附屬公司，「本集團」）董 事會（「董事會」）茲通告，本公司謹定於二零二五年八月二十九日（星期五）舉行董 事會會議，以（其中包括）考慮及批准本集團截至二零二五年六月三十日止六個月 的中期業績及其刊發，派發中期股息（如有），以及處理其他事項。 承董事會命 深圳市海普瑞藥業集團股份有限公司 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） 中國深圳 二零二五年八月十五日 於本公告日期，本公司執行董事為李鋰先生、李坦女士、單宇先生及張平先生； 本公司獨立非執行董事為呂川博士、黃鵬先生及易銘先生。 ...

Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company, highlighting its revenue structure, market position, and recent financial results [2][7]. Company Overview - Haiprime was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company aims to provide high-quality, safe, and effective medications and services to global patients [2]. Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, with a growth of 1.00% [7]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Revenue Composition - The revenue composition of Haiprime includes: - Formulations: 56.55% - Heparin sodium and low molecular weight heparin raw materials: 20.25% - CDMO: 19.58% - Others: 3.63% [7]. Market Activity - On August 15, Haiprime's stock increased by 0.23%, with a trading volume of 87.155 million yuan and a turnover rate of 0.53%, leading to a total market capitalization of 19.427 billion yuan [1]. - The stock has seen a net outflow of 8.7532 million yuan from major investors, indicating a lack of strong buying interest [4][5]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with respective holdings of 4.9411 million shares and 4.6859 million shares, both showing increases from the previous period [8].

Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company in China, highlighting its revenue structure, market position, and recent financial results. Company Overview - Haiprime was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development and commercialization [2][7] - The company aims to provide high-quality, safe, and effective medications and services to global patients [2] Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7] - As of March 31, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3] Revenue Composition - The revenue composition of Haiprime includes: - Formulations: 56.55% - Heparin sodium and low molecular weight heparin raw materials: 20.25% - CDMO: 19.58% - Others: 3.63% [7] Market Activity - On August 14, Haiprime's stock fell by 1.42%, with a trading volume of 92.2413 million yuan and a turnover rate of 0.55%, resulting in a total market capitalization of 19.383 billion yuan [1] - The stock's average trading cost is 11.38 yuan, with current price levels between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6] Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period, with the average circulating shares per person remaining at zero [7][8] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]

Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company, highlighting its revenue structure, market position, and recent financial results. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, operates in the heparin industry, biopharmaceutical CDMO, and innovative drug development, aiming to provide high-quality medications globally [2][7]. - The company has a dual financing platform (A+H shares) and focuses on the production and commercialization of heparin and other pharmaceutical products [2][7]. Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On August 12, Haiprime's stock price decreased by 0.53%, with a trading volume of 56.64 million yuan and a market capitalization of 19.178 billion yuan [1]. - The stock's average trading cost is 11.35 yuan, with current price levels between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with both increasing their holdings [8].

Group 1 - The Shanghai Composite Index rose by 0.96%, closing at 3617.6 points, while the Hang Seng Index increased by 0.68%, closing at 24902.53 points [1] - The premium of Haiprui's A-shares over H-shares reached 125.21%, ranking 16th among AH shares [1] - Haiprui's A-shares closed at 13.26 yuan, with a gain of 0.68%, and H-shares closed at 6.43 HKD, up by 3.38% [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company's main business covers the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic, driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

Group 1 - The Shanghai Composite Index rose by 0.66% to close at 3583.31 points, while the Hang Seng Index increased by 0.92% to 24733.45 points [1] - The premium of Haiprui's A-shares over H-shares reached 131.61%, ranking 14th among AH shares in terms of premium rate [1] - Haiprui's A-shares closed at 13.17 yuan, down 0.6%, and H-shares closed at 6.22 Hong Kong dollars, remaining flat [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company operates across the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic and driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]